1. In Vivo
  2. >>Leadership

Mironid On Reducing The Burden Of Polycystic Kidney Disease

ADPKD Is The Most Common Genetic Kidney Disease

 
• By Chloe Kent

Scottish biotech Mironid is in the preclinical stages of developing a treatment for autosomal dominant polycystic kidney disease, a genetic condition which for around half of patients can led to kidney failure by the time they reach 60 years of age. In Vivo spoke to chief medical officer Cass Kelleher about the company’s development strategy.

Doctor holding a plastic model of a polycystic kidney
Around half of ADPKD patients will be in kidney failure by the time they are 60 • Source: Shutterstock

For patients with autosomal dominant polycystic kidney disease (ADKPD), abnormalities in two different genes – PKD1, which accounts for around 78% of cases, and PKD2, which accounts for around 15% – disrupt the regular development of the kidneys and cause cysts to grow, due to abnormally elevated levels of cyclic adenosine monophosphate (cAMP) enzymes.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Leadership

Building The Worm Atlas For I&I Breakthroughs

 
• By Ian Taylor

The next big thing in auto-immune therapies: worms. Or so a young California biotech believes. Holoclara is pioneering a new class of medicines derived from intestinal worms to revolutionize the treatment of autoimmune diseases, allergies, and more.

Podcast: OSE Immunotherapeutics’ CEO On Ulcerative Colitis Asset

 
• By David Wild

Nicolas Poirier, CEO of French biotech OSE Immunotherapeutics, spoke with In Vivo about the company's anti-IL-7R antibody, lusvertikimab, on the heels of impressive ulcerative colitis data presented at the 2025 European Crohn's and Colitis Organization meeting.

Rising Leaders 2025: Partnerships Propel Crystal Qin’s LaNova To Record-Breaking Merck Deal

 
• By Brian Yang

Crystal Qin has led LaNova Medicines’ swift rise in the biotech world through strategic partnerships and innovative R&D, highlighted by a record deal with big pharma.

Rising Leaders 2025: Amir Hefni Puts Optimism Into Action At Resolution Therapeutics

 
• By Jo Shorthouse

In Vivo Rising Leader Amir Hefni, CEO of Resolution Therapeutics, discusses the company's advancements in macrophage cell therapies for inflammatory and fibrotic diseases, and his transition from big pharma to biotech leadership.

More from In Vivo

Rising Leaders 2025: Partnerships Propel Crystal Qin’s LaNova To Record-Breaking Merck Deal

 
• By Brian Yang

Crystal Qin has led LaNova Medicines’ swift rise in the biotech world through strategic partnerships and innovative R&D, highlighted by a record deal with big pharma.

Rising Leaders 2025: Amir Hefni Puts Optimism Into Action At Resolution Therapeutics

 
• By Jo Shorthouse

In Vivo Rising Leader Amir Hefni, CEO of Resolution Therapeutics, discusses the company's advancements in macrophage cell therapies for inflammatory and fibrotic diseases, and his transition from big pharma to biotech leadership.

In Vivo’s 2025 Rising Leaders

 
• By Jo Shorthouse

The sixth annual edition of In Vivo’s Rising Leaders features entrepreneurs, academics, lawyers, regulators and innovators from around the globe, representing the forefront of creativity in health care.